Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon

Table 3

Univariate analysis of clinicopathological indicators and pCR.

	Number of cases	Number of pCR	Percentage of pCR	value
Age				0.615
≤60	67	30	45%
>60	20	7	35%
Menstrual status				0.664
Menopause	45	20	44%
Premenopause	30	11	37%
T stage				0.663
T1-T2-T3	70	31	44%
T4	17	6	35%
N stage				0.374
N0	12	3	25%
N1-N2-N3-Nx	75	34	45%
ER				0.461
Negative	27	14	52%
Positive	60	23	38%
PR				0.169
Negative	40	22	55%
Positive	47	15	32%
HER2				0.151
Negative	47	15	32%
Positive	39	22	56%
Ki67				0.606
≤14	30	11	37%
>14	57	26	46%
Chemotherapy				0.911
AC	51	23	45%
No AC	6	3	50%